One of the problems with AI is that it narrowly answers based on the questions asked of it. The valuation does not take into account the broad spectrum of diseases that leronlimab can potentially treat. With approval in Alzheimer's even cornering 15% of the market would mean substantially more. $36 billion in revenue, $3.6 billion in earnings and a $47 dollar share price with a reasonable P/E. With no really effective drug out there we could possibly see 30% of the market and $94 a share. That would make a $1.66 to $8 a share buyout seem rather paltry.